EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics

Tina Deyhim, Adam S Cheifetz, Konstantinos Papamichael iD

Journal of Clinical Medicine · 16.11.2023 · 12 (22) · 7132

DOI: 10.3390/jcm12227132 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.11.2023. Verfasst von Tina Deyhim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biological therapy is very effective for treating patients with moderate to severe inflammatory bowel disease (IBD). However, up to 40% can have primary non-response, and up to 50% of the patients can experience a loss of response to anti-tumor necrosis factor therapy. These undesirable outcomes can be attributed to either a mechanistic failure or pharmacokinetic (PK) issues characterized by an inadequate drug exposure and a high drug clearance. There are several factors associated with accelerated clearance of biologics including increased body weight, low serum albumin and immunogenicity. Drug clearance has gained a lot of attention recently as cumulative data suggest that there is an association between drug clearance and therapeutic outcomes in patients with IBD. Moreover, clearance is used by model informed precision dosing (MIDP) tools, or PK dashboards, to adjust the dosing for reaching a target drug concentration threshold towards a more personalized application of TDM. However, the role of drug clearance in clinical practice is yet to be determined. This comprehensive review aims to present data regarding the variables affecting the clearance of specific biologics, the association of clearance with therapeutic outcomes and the role of clearance monitoring and MIPD in patients with IBD.

Schlagwörter

Stichwörter der Autor:innen

anti-TNF therapyclearanceinflammatory bowel diseasemirikizumabmodel informed precision dosingpharmacokinetic dashboardrisankizumabtherapeutic drug monitoringustekinumabvedolizumab

Autor:innen und Institutionen

  • Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

ORCID-Profile: Konstantinos Papamichael

Zitieren

APA

Deyhim, T., Cheifetz, A. S., & Papamichael, K. (2023). Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics. Journal of Clinical Medicine, 12(22), 7132. https://doi.org/10.3390/jcm12227132

Vancouver

Deyhim T, Cheifetz AS, Papamichael K. Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics. Journal of Clinical Medicine. 2023;12(22):7132. doi:10.3390/jcm12227132

BibTeX
@article{Deyhim2023,
  author = {Deyhim, Tina and Cheifetz, Adam S and Papamichael, Konstantinos},
  title = {Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {22},
  pages = {7132},
  doi = {10.3390/jcm12227132}
}
Kostenlos starten →